Compare Davita Inc (DVA) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Schwab US Large Cap Growth ETF — how do they compare? Davita Inc trades at $230.53 (market cap $14.92B), while Schwab US Large Cap Growth ETF trades at $34.67. Which is the better fit depends on your goals.
| DVA | SCHG | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Sector/Thematic |
52-Week High | $235.71 | $35.30 |
52-Week Low | $103.87 | $28.10 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
SCHG, the Schwab U.S. Large-Cap Growth ETF, trades at $34.37, down 0.81% on the day. The technical outlook is bullish with moving averages signaling strength, while oscillators are neutral. Recent news highlights its concentrated exposure to AI-driven tech giants like Nvidia, Apple, and Microsoft, positioning it for potential growth from AI capital expenditure trends. The fund's portfolio carries a P/E around 32x, reflecting premium valuations amid moderate 2026 performance.
Outlook: SCHG offers leveraged growth potential through top tech holdings but faces risks from high concentration and interest rate sensitivity. Upside hinges on AI adoption, while downside could stem from tech sector volatility or economic shifts. Institutional inflows suggest confidence, yet investors must weigh valuation against diversification limits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
